HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peng Gao Selected Research

Transient Receptor Potential Channels

1/2022TRPC5 deletion in the central amygdala antagonizes high-fat diet-induced obesity by increasing sympathetic innervation.
11/2020Activation of the bitter taste sensor TRPM5 prevents high salt-induced cardiovascular dysfunction.
1/2020Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes.
1/2020Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction.
10/2019Impairment of Bitter Taste Sensor Transient Receptor Potential Channel M5-Mediated Aversion Aggravates High-Salt Intake and Hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peng Gao Research Topics

Disease

227Neoplasms (Cancer)
11/2022 - 06/2004
63Stomach Neoplasms (Stomach Cancer)
06/2022 - 06/2009
59Breast Neoplasms (Breast Cancer)
03/2022 - 12/2003
49Neoplasm Metastasis (Metastasis)
06/2022 - 02/2005
46Inflammation (Inflammations)
01/2022 - 11/2010
27Infections
06/2022 - 01/2012
26Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 01/2012
24Carcinogenesis
10/2019 - 11/2007
18Lung Neoplasms (Lung Cancer)
10/2021 - 11/2008
17Hypertension (High Blood Pressure)
01/2022 - 12/2011
13COVID-19
04/2022 - 01/2020
12Colonic Neoplasms (Colon Cancer)
07/2022 - 11/2010
12Lymphatic Metastasis
01/2022 - 10/2004
12Pathologic Constriction (Stenosis)
01/2022 - 02/2015
12Asthma (Bronchial Asthma)
11/2021 - 12/2013
12Hepatocellular Carcinoma (Hepatoma)
08/2021 - 08/2013
12Prostatic Neoplasms (Prostate Cancer)
01/2021 - 11/2010
12Carcinoma (Carcinomatosis)
11/2020 - 10/2004
11Pain (Aches)
03/2022 - 04/2007
11Glioma (Gliomas)
02/2022 - 12/2014
10Stroke (Strokes)
01/2022 - 03/2011
10Rectal Neoplasms (Rectal Cancer)
11/2021 - 11/2013
10Body Weight (Weight, Body)
12/2020 - 07/2011
9Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2022 - 12/2017
9Glioblastoma (Glioblastoma Multiforme)
05/2022 - 03/2016
9Hypoxia (Hypoxemia)
08/2021 - 06/2006
8Atrial Fibrillation
07/2022 - 04/2010
8Fibrosis (Cirrhosis)
07/2022 - 08/2013
8Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 01/2016
8Diabetic Nephropathies (Diabetic Nephropathy)
10/2021 - 01/2018
8Wounds and Injuries (Trauma)
06/2021 - 04/2007
7Ischemic Stroke
01/2022 - 03/2011
7Thrombosis (Thrombus)
12/2021 - 12/2010
7Hyperplasia
12/2021 - 11/2007
7Heart Failure
01/2021 - 04/2010
7Atherosclerosis
12/2020 - 02/2003
6Alzheimer Disease (Alzheimer's Disease)
01/2022 - 04/2013
6Hyperglycemia
01/2022 - 08/2015
6Fever (Fevers)
03/2020 - 01/2011
5Polyps
07/2022 - 10/2004
5Leukemia
01/2022 - 06/2013
5Mitochondrial Diseases (Mitochondrial Disease)
01/2022 - 12/2015
5Obesity
01/2022 - 02/2015
5Atherosclerotic Plaque (Atheroma)
01/2022 - 12/2011
5Osteosarcoma (Osteogenic Sarcoma)
01/2021 - 04/2015

Drug/Important Bio-Agent (IBA)

74Proteins (Proteins, Gene)FDA Link
07/2022 - 10/2004
54Biomarkers (Surrogate Marker)IBA
07/2022 - 03/2006
48Pharmaceutical PreparationsIBA
05/2022 - 06/2004
38MicroRNAs (MicroRNA)IBA
01/2022 - 06/2011
24Messenger RNA (mRNA)IBA
04/2022 - 10/2004
24Biological ProductsIBA
01/2022 - 06/2006
22Long Noncoding RNAIBA
06/2022 - 11/2014
20RNA (Ribonucleic Acid)IBA
03/2022 - 05/2012
18CytokinesIBA
06/2022 - 04/2010
13EnzymesIBA
01/2022 - 04/2010
11Anti-Bacterial Agents (Antibiotics)IBA
06/2022 - 07/2012
11DNA (Deoxyribonucleic Acid)IBA
01/2022 - 07/2009
11Phosphotransferases (Kinase)IBA
01/2022 - 01/2011
11LipidsIBA
10/2021 - 12/2011
11Reactive Oxygen Species (Oxygen Radicals)IBA
10/2021 - 04/2013
11Small Interfering RNA (siRNA)IBA
01/2021 - 03/2005
10Glucose (Dextrose)FDA LinkGeneric
03/2022 - 01/2019
10SaltsIBA
01/2022 - 12/2015
10CalciumIBA
01/2022 - 01/2017
10Sirtuin 1IBA
12/2021 - 02/2011
10Indicators and Reagents (Reagents)IBA
11/2021 - 06/2006
9Doxorubicin (Adriamycin)FDA LinkGeneric
02/2021 - 07/2004
8VaccinesIBA
04/2022 - 01/2011
8Therapeutic UsesIBA
10/2021 - 12/2007
8AntigensIBA
08/2021 - 01/2015
8Transcription Factors (Transcription Factor)IBA
01/2021 - 05/2008
8Progesterone Receptors (Progesterone Receptor)IBA
01/2021 - 05/2012
7Angiotensin IIIBA
11/2020 - 02/2011
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2020 - 08/2009
7Cadherins (E-Cadherin)IBA
01/2019 - 04/2005
6Immune Checkpoint InhibitorsIBA
09/2022 - 01/2018
6Metal-Organic FrameworksIBA
06/2022 - 01/2021
6Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2021 - 11/2014
6Fluorouracil (Carac)FDA LinkGeneric
12/2020 - 11/2014
6Estrogen ReceptorsIBA
11/2020 - 05/2012
6Amino AcidsFDA Link
01/2018 - 11/2010
6Complementary DNA (cDNA)IBA
05/2015 - 02/2003
6ceramide glucosyltransferaseIBA
12/2012 - 02/2005
5AntioxidantsIBA
07/2022 - 05/2015
5Liposomes (Liposome)IBA
01/2022 - 06/2006
5purineIBA
01/2022 - 11/2010
5Transient Receptor Potential ChannelsIBA
01/2022 - 10/2019
5CateninsIBA
12/2021 - 10/2012
5Antiviral Agents (Antivirals)IBA
12/2021 - 09/2012

Therapy/Procedure

85Therapeutics
06/2022 - 01/2009
40Drug Therapy (Chemotherapy)
01/2022 - 04/2006
14Radiotherapy
09/2021 - 05/2016
10Neoadjuvant Therapy
11/2021 - 11/2014
9Stents
12/2021 - 12/2010
9Length of Stay
06/2021 - 04/2007
7Immunotherapy
02/2022 - 02/2017
7Adjuvant Chemotherapy
07/2021 - 04/2016
6Catheter Ablation
07/2022 - 07/2013
6Gastrectomy
02/2021 - 11/2012
6Aftercare (After-Treatment)
06/2020 - 01/2014